News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Mar 19, 2020

Summary Toggle aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th

Management to host conference call and webcast at 5:00 pm EST / 2:00 pm PST SAN DIEGO , March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today
Mar 17, 2020

Summary Toggle Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor

Dr. Mercurio to advise company on the development of novel antibody therapeutics targeting neuropilin-2 (NRP2) for cancer SAN DIEGO , March 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based
Mar 10, 2020

Summary Toggle aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

SAN DIEGO , March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public offering of common
Mar 3, 2020

Summary Toggle aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO , March 03, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present an abstract in a poster session at the
Feb 27, 2020

Summary Toggle aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology

Paper highlights the essential role that histidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states Lead therapeutic candidate, ATYR1923, being evaluated in a Phase 1b/2a trial in patients with pulmonary sarcoidosis SAN DIEGO , Feb.
Feb 6, 2020

Summary Toggle aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering

SAN DIEGO , Feb. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the pricing of an underwritten public offering of 4,235,294 shares of its
Jan 6, 2020

Summary Toggle aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan

aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties Kyorin to fund all ATYR1923 development and commercialization activities in Japan SAN DIEGO , Jan. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
Dec 12, 2019

Summary Toggle aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923

ATYR1923 safe and well tolerated in initial 15 randomized patients with pulmonary sarcoidosis No drug-related serious adverse events observed SAN DIEGO , Dec. 12, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of
Nov 14, 2019

Summary Toggle aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update

Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019 Company to host conference call and webcast today, November 14 , at 5:00pm EDT SAN DIEGO , Nov. 14, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
Nov 13, 2019

Summary Toggle aTyr Pharma to Present at the Stifel Healthcare Conference 2019

SAN DIEGO , Nov. 13, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Dr. Sanjay Shukla , President and Chief Executive Officer of aTyr,